Phase I and II clinical trials of haNK, alone, or in combination with anti-PD-L1 Ab (avelumab), a cancer vaccine, or super-IL-15, are ongoing for the treatment of triple negative breast cancer, squamous cell carcinoma, Merkel cell carcinoma, pancreatic cancer, and other types of cancers (NCT03027128, NCT03387085, NCT03387111, NCT03853317, and NCT03586869). This evidence concerns the gene CD274 and squamous cell carcinoma.